McCaig Institute for Bone and Joint Health, Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, AB, T2N 4N1, Canada.
Department Cell Biology and Anatomy, University of Calgary, Calgary, AB, Canada.
Stem Cell Res Ther. 2023 Jun 25;14(1):168. doi: 10.1186/s13287-023-03396-3.
Osteoarthritis (OA) is a chronic debilitating disease impacting a significant percentage of the global population. While there are numerous surgical and non-invasive interventions that can postpone joint replacement, there are no current treatments which can reverse the joint damage occurring during the pathogenesis of the disease. While many groups are investigating the use of stem cell therapies in the treatment of OA, we still don't have a clear understanding of the role of these cells in the body, including heterogeneity of tissue resident adult mesenchymal progenitor cells (MPCs).
In the current study, we examined MPCs from the synovium and individuals with or without a traumatic knee joint injury and explored the chondrogenic differentiation capacity of these MPCs in vitro and in vivo.
We found that there is heterogeneity of MPCs with the adult synovium and distinct sub-populations of MPCs and the abundancy of these sub-populations change with joint injury. Furthermore, only some of these sub-populations have the ability to effect cartilage repair in vivo. Using an unbiased proteomics approach, we were able to identify cell surface markers that identify this pro-chondrogenic MPC population in normal and injured joints, specifically CD82CD59 synovial MPCs have robust cartilage regenerative properties in vivo.
The results of this study clearly show that cells within the adult human joint can impact cartilage repair and that these sub-populations exist within joints that have undergone a traumatic joint injury. Therefore, these populations can be exploited for the treatment of cartilage injuries and OA in future clinical trials.
骨关节炎(OA)是一种慢性致残性疾病,影响着全球很大一部分人口。虽然有许多手术和非侵入性干预措施可以推迟关节置换,但目前还没有可以逆转疾病发病过程中发生的关节损伤的治疗方法。虽然许多团体都在研究干细胞疗法在 OA 治疗中的应用,但我们仍然不清楚这些细胞在体内的作用,包括组织驻留的成年间充质祖细胞(MPCs)的异质性。
在本研究中,我们检查了来自滑膜的 MPCs 和有无创伤性膝关节损伤的个体,并探讨了这些 MPCs 在体外和体内的软骨分化能力。
我们发现成人滑膜中的 MPCs 存在异质性,存在不同的 MPC 亚群,这些亚群的丰度随着关节损伤而变化。此外,只有这些亚群中的一些具有体内软骨修复的能力。使用无偏蛋白质组学方法,我们能够鉴定出识别正常和受伤关节中这种促软骨形成 MPC 群体的细胞表面标志物,即 CD82CD59 滑膜 MPCs 在体内具有很强的软骨再生特性。
本研究的结果清楚地表明,成人关节内的细胞可以影响软骨修复,并且这些亚群存在于经历过创伤性关节损伤的关节中。因此,这些群体可以在未来的临床试验中用于治疗软骨损伤和 OA。